4.8 Article

Aberrant MCM10 SUMOylation induces genomic instability mediated by a genetic variant associated with survival of esophageal squamous cell carcinoma

Journal

CLINICAL AND TRANSLATIONAL MEDICINE
Volume 11, Issue 6, Pages -

Publisher

JOHN WILEY & SONS LTD
DOI: 10.1002/ctm2.485

Keywords

ESCC; genomic instability; MCM10; SUMOylation; survival

Funding

  1. Natural Science Foundation of Hubei Province [2019CFA009]
  2. National Science Fund for Distinguished Young Scholars of China [NSFC-81925032]
  3. NationalNatural Science Foundation of China [NSFC81673256, NSFC-81872696]
  4. Program for HUST Academic Frontier Youth Team
  5. National Program for Support of Top-notchYoung Professionals
  6. CAST [2018QNRC001]

Ask authors/readers for more resources

The study identified a germline variant (rs2274110) in the MCM10 gene associated with ESCC prognosis, with individuals carrying the AA genotype having poorer survival outcomes. This variant increased SUMOylation levels of the MCM10 protein, leading to its overexpression and contributing to the proliferation and metastasis abilities of ESCC cells. MCM10 inhibitors, such as Suramin, were shown to effectively block ESCC cell metastasis.
Background Esophageal squamous cell carcinoma (ESCC) is one of the common gastrointestinal malignancy with an inferior prognosis outcome. DNA replication licensing aberration induced by dysregulation of minichromosome maintenance proteins (MCMs) causes genomic instability and cancer metastasis. SUMOylation modification plays a pivotal role in regulation of genomic integrity, while its dysregulation fueled by preexisting germline variants in cancers remains poorly understood. Methods Firstly, we conducted two-stage survival analysis consisting of an exome-wide association study in 904 ESCC samples and another independent 503 ESCC samples. Then, multipronged functional experiments were performed to illuminate the potential biological mechanisms underlying the promising variants, and MCM10 influences the ESCC progression. Finally, we tested the effects of MCM10 inhibitors on ESCC cells. Results A germline variant rs2274110 located at the exon 15 of MCM10 was identified to be significantly associated with the prognosis of ESCC patients. Individuals carrying rs2274110-AA genotypes confer a poor survival (hazard ratio = 1.61, 95% confidence interval = 1.35-1.93, p = 1.35 x 10(-7)), compared with subjects carrying rs2274110-AG/GG genotypes. Furthermore, we interestingly found that the variant can increase SUMOylation levels at K669 site (Lys[K]699Arg[R]) of MCM10 protein mediated by SUMO2/3 enzymes, which resulted in an aberrant overexpression of MCM10. Mechanistically, aberrant overexpression of MCM10 facilitated the proliferation and metastasis abilities of ESCC cells in vitro and in vivo by inducing DNA over-replication and genomic instability, providing functional evidence to support our population finding that high expression of MCM10 is extensively presented in tumor tissues of ESCC and correlated with inferior survival outcomes of multiple cancer types, including ESCC. Finally, MCM10 inhibitors Suramin and its analogues were revealed to effectively block the metastasis of ESCC cells. Conclusions These findings not only demonstrate a potential biological mechanism between aberrant SUMOylation, genomic instability and cancer metastasis, but also provide a promising biomarker aiding in stratifying ESCC individuals with different prognosis, as well as a potential therapeutic target MCM10.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available